Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159323 | 0.83 | SYK (0.78) | SYKHTR1ADRD2EGFRERBB2 | |
| SCHEMBL29638125 | 0.83 | SYK (0.78) | SYKHTR1ADRD2EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL6239858 | 0.81 | SYK (0.76) | SYKSMN1; SMN2TP53HTTHTR1A | |
| Ammonia Solution, Strong SCHEMBL23859934 | 0.81 | SYK (0.76) | SYKHTR1ADRD2EGFRERBB2 | |
| SCHEMBL30354882 | 0.80 | SYK (0.43) | SYKNPC1RAB9AMAPTTSHR | |
| SCHEMBL27096917 | 0.79 | SYK (0.47) | SYKMRGPRX4NPC1RAB9AMAPT | |
| SCHEMBL20584175 | 0.79 | SYK (0.47) | SYKMRGPRX4NPC1RAB9AMAPT | |
| SCHEMBL30354815 | 0.79 | GAA (0.58) | SYKNPC1RAB9AMAPTTSHR | |
| SCHEMBL632895 | 0.78 | MRGPRX4 (0.57) | SYKMRGPRX4NPC1RAB9AMAPT | |
| SCHEMBL21835398 | 0.77 | SYK (0.55) | SYKMRGPRX4NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | SYK 102/4885MRGPRX4 3359/4885NPC1 4309/4885 |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | SYK 318/4885MRGPRX4 1362/4885NPC1 4408/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885MRGPRX4 3359/4885NPC1 4309/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | SYK 146/4885MRGPRX4 1072/4885NPC1 4538/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885MRGPRX4 3359/4885NPC1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.